Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Ledipasvir / Sofosbuvir (Harvoni & authorized generic by Quarter
Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — Rest of World sales ($M) ($M)
Gilead Sciences Ledipasvir / Sofosbuvir (Harvoni & authorized generic: $5M in Q4 2023, down 37.5% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 5 | -37.5% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2023 | Sep 30, 2023 | 4 | -66.7% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 5 | -61.5% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 5 | -72.2% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 8 | -61.9% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 12 | -53.8% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 13 | -55.2% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 18 | -14.3% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2021 | Dec 31, 2021 | 21 | -22.2% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 26 | -29.7% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 29 | -25.6% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 21 | -56.2% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 27 | -28.9% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 37 | -33.9% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 39 | -54.1% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 48 | -40.7% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 38 | -25.5% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 56 | -36.4% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 85 | +7.6% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 81 | +39.7% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 51 | -48.0% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 88 | -39.3% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 79 | -53.0% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 58 | -71.3% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 98 | – | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 145 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 168 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2017 | Mar 31, 2017 | 202 | – | Form 10-Q (filed 2018-05-09) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Ledipasvir / Sofosbuvir (Harvoni & authorized generic ($M), quarterly Q1 2017–Q4 2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-harvoni-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.